Sotera Health (NYSE:SHC) Downgraded by TheStreet

TheStreet cut shares of Sotera Health (NYSE:SHCGet Rating) from a c- rating to a d rating in a report released on Monday morning, TheStreetRatingsTable reports.

Several other brokerages have also commented on SHC. The Goldman Sachs Group lowered Sotera Health from a buy rating to a neutral rating and dropped their price target for the stock from $23.00 to $9.00 in a research note on Tuesday. JPMorgan Chase & Co. downgraded shares of Sotera Health from an overweight rating to an underweight rating and dropped their target price for the stock from $26.00 to $9.00 in a research report on Wednesday. Barclays reduced their price target on shares of Sotera Health from $24.00 to $22.00 and set an equal weight rating on the stock in a research report on Wednesday, July 13th. Finally, Wolfe Research lowered shares of Sotera Health from an outperform rating to a peer perform rating and set a $26.00 price objective for the company. in a research report on Thursday, June 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and a consensus price target of $20.86.

Sotera Health Price Performance

Sotera Health stock opened at $7.41 on Monday. Sotera Health has a 1 year low of $7.11 and a 1 year high of $27.38. The company has a debt-to-equity ratio of 2.83, a quick ratio of 2.53 and a current ratio of 2.81. The firm has a 50 day moving average price of $17.33 and a 200 day moving average price of $19.53. The company has a market cap of $2.10 billion, a price-to-earnings ratio of 16.47 and a beta of 0.44.

Sotera Health (NYSE:SHCGet Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.04. The company had revenue of $266.40 million during the quarter, compared to analysts’ expectations of $256.30 million. Sotera Health had a net margin of 12.82% and a return on equity of 41.00%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.25 EPS. Sell-side analysts predict that Sotera Health will post 0.91 earnings per share for the current year.

Institutional Trading of Sotera Health

A number of hedge funds have recently made changes to their positions in SHC. Ensign Peak Advisors Inc purchased a new stake in shares of Sotera Health during the fourth quarter worth about $122,000. MetLife Investment Management LLC purchased a new stake in Sotera Health during the 1st quarter worth approximately $139,000. Federated Hermes Inc. purchased a new stake in Sotera Health during the 1st quarter worth approximately $157,000. Securian Asset Management Inc. acquired a new position in shares of Sotera Health in the 2nd quarter valued at approximately $177,000. Finally, State of Alaska Department of Revenue purchased a new position in shares of Sotera Health during the 1st quarter valued at approximately $203,000. Hedge funds and other institutional investors own 88.38% of the company’s stock.

About Sotera Health

(Get Rating)

Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.

Featured Stories

Analyst Recommendations for Sotera Health (NYSE:SHC)

Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.